Safety and activity of nivolumab (nivo) monotherapy and nivo in combination with ipilimumab (ipi) in recurrent glioblastoma (GBM): Updated results from checkmate-143.

被引：49
|
作者：
Reardon, David A.
Sampson, John H.
Sahebjam, Solmaz
Lim, Michael
Baehring, Joachim M.
Vlahovic, Gordana
Cloughesy, Timothy Francis
Strauss, Lewis C.
Latek, Robert Raymond
Paliwal, Prashni
Harbison, Christopher T.
Voloschin, Alfredo Daniel
Omuro, Antonio Marcilio Padula
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.2014
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2014
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Preliminary safety and activity of nivolumab and its combination with ipilimumab in recurrent glioblastoma (GBM): CHECKMATE-143.
    Sampson, John H.
    Vlahovic, Gordana
    Sahebjam, Solmaz
    Omuro, Antonio Marcilio Padula
    Baehring, Joachim M.
    Hafler, David A.
    Voloschin, Alfredo Daniel
    Paliwal, Prashni
    Grosso, Joseph
    Coric, Vlad
    Cloughesy, Timothy F.
    Lim, Michael
    Reardon, David A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [2] Safety and Activity of Nivolumab ± Ipilimumab in Recurrent Glioblastoma: Updated Results From CHECKMATE-143
    Sampson, John H.
    Omuro, Antonio
    Vlahovic, Gordana
    Sahebjam, Solmaz
    Baehring, Joachim
    Hafler, David
    Voloschin, Alfredo
    Latek, Robert
    Cloughesy, Timothy
    Lim, Michael
    Reardon, David
    JOURNAL OF NEUROSURGERY, 2016, 124 (04) : A1189 - A1190
  • [3] Nivolumab (nivo) in combination with radiotherapy (RT) ± temozolomide (TMZ): Updated safety results from CheckMate 143 in pts with methylated or unmethylated newly diagnosed glioblastoma (GBM)
    Lim, M.
    Omuro, A.
    Vlahovic, G.
    Reardon, D. A.
    Sahebjam, S.
    Cloughesy, T.
    Baehring, J.
    Butowski, N.
    Potter, V.
    Zwirtes, R.
    Paliwal, P.
    Carleton, M.
    Sampson, J.
    Brandes, A. A.
    ANNALS OF ONCOLOGY, 2017, 28
  • [4] NIVOLUMAB (NIVO) MONOTHERAPY OR IN COMBINATION WITH IPILIMUMAB (IPI) FOR TREATMENT OF RECURRENT SMALL CELL LUNG CANCER (SCLC)
    Calvo, Emiliano
    Lopez-Martin, Jose
    Bendell, Johanna
    Eder, Joseph P.
    Taylor, Matthew
    Ott, Patrick A.
    Pietanza, M. Catherine
    Horn, Leora
    Jaeger, Dirk
    de Braud, Filippo
    Morse, Michael A.
    Ascierto, Paolo A.
    Le, Dung T.
    Amin, Asim
    Evans, Jeff
    Simon, Jason S.
    Lin, Chen-Sheng
    Christensen, Olaf
    Antonia, Scott J.
    Asia-Pacific Journal of Clinical Oncology, 2015, 11 : 118 - 118
  • [5] Nivolumab (NIVO) monotherapy or in combination with ipilimumab (IPI) for treatment of recurrent small cell lung cancer (SCLC)
    Calvo, E.
    Lopez-Martin, J. A.
    Bendell, J.
    Eder, J. P.
    Taylor, M.
    Ott, P. A.
    Pietanza, M. C.
    Horn, L.
    Jaeger, D.
    De Braud, F.
    Morse, M. A.
    Ascierto, P. A.
    Le, D. T.
    Amin, A.
    Evans, J.
    Simon, J.
    Lin, C. S.
    Christensen, O.
    Antonia, S. J.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S633 - S633
  • [6] Updated results from a phase I study of nivolumab (Nivo) in combination with ipilimumab (Ipi) in metastatic renal cell carcinoma (mRCC): The CheckMate 016 study
    Hammers, H.
    Plimack, E. R.
    Infante, J. R.
    Rini, B. I.
    McDermott, D.
    Lewis, L.
    Voss, M. H.
    Sharma, P.
    Pal, S. K.
    Razak, A.
    Kollmannsberger, C. K.
    Heng, D.
    Spratlin, J.
    McHenry, B.
    Gagnier, P.
    Amin, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [7] Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204).
    Tawbi, Hussein Abdul-Hassan
    Forsyth, Peter A. J.
    Hodi, F. Stephen
    Lao, Christopher D.
    Moschos, Stergios J.
    Hamid, Omid
    Atkins, Michael B.
    Lewis, Karl D.
    Thomas, Reena Parada
    Glaspy, John A.
    Jang, Sekwon
    Algazi, Alain Patrick
    Khushalani, Nikhil I.
    Postow, Michael A.
    Pavlick, Anna C.
    Ernstoff, Marc S.
    Reardon, David A.
    Balogh, Agnes
    Rizzo, Jasmine I.
    Margolin, Kim Allyson
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] NRG BN002: SAFETY DATA FROM A PHASE I STUDY OF IPILIMUMAB (IPI), NIVOLUMAB (NIVO), AND THE COMBINATION FOR NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
    Gilbert, Mark
    Zhang, Peixin
    Sloan, Andrew
    Aldape, Kenneth
    Wu, Jing
    Rogers, Lisa
    Wen, Patrick
    Barani, Igor
    Iwamoto, Fabio
    Raval, Raju
    Voloshin, Alfredo
    de Groot, John
    Won, Minhee
    Mehta, Minesh P.
    NEURO-ONCOLOGY, 2018, 20 : 7 - 7
  • [9] Efficacy and safety of nivolumab (Nivo) plus ipilimumab (Ipi) in patients (pts) with recurrent/metastatic (R/M) cervical cancer: Results from CheckMate 358
    Naumann, R. W.
    Oaknin, A.
    Meyer, T.
    Lopez-Picazo, J. M.
    Lao, C.
    Bang, Y-J.
    Boni, V.
    Sharfman, W. H.
    Park, J. C.
    Devriese, L. A.
    Harano, K.
    Chung, C. H.
    Topalian, S. L.
    Zaki, K.
    Chen, T.
    Gu, J.
    Li, B.
    Barrows, A.
    Horvath, A.
    Moore, K. N.
    ANNALS OF ONCOLOGY, 2019, 30 : 898 - +
  • [10] Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (MBM; CheckMate 204)
    Tawbi, Hussein
    Forsyth, Peter
    Hodi, F. Stephen
    Lao, Christopher
    Moschos, Stergios
    Hamid, Omid
    Atkins, Michael B.
    Lewis, Karl
    Thomas, Reena P.
    Glaspy, John A.
    Jang, Sekwon
    Algazi, Alain
    Khushalani, Nikhil I.
    Postow, Michael A.
    Pavlick, Anna C.
    Ernstoff, Marc
    Reardon, David A.
    Balogh, Agnes
    Rizzo, Jasmine
    Margolin, Kim
    BRITISH JOURNAL OF CANCER, 2019, 121 : 20 - 20
12345